# Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

> **NCT00324363** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 466 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** exenatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00324363
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2015-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324363, "Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00324363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*